![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Neuroelectrics’ Epilepsy Device Gets FDA Breakthrough Device Designation
Neuroelectrics’ Epilepsy Device Gets FDA Breakthrough Device Designation
![Neuroelectrics-Logo.png](https://www.fdanews.com/ext/resources/test/Device_Images6/Neuroelectrics-Logo.png?t=1625611289&width=430)
Brain stimulation therapy company Neuroelectrics has received the FDA’s Breakthrough Device designation for its Starstim neuromodulation platform used for treatment of drug-resistant epilepsy.
The Starstim device, which does not require a hospital setting, combines transcranial electrical stimulation with personalized treatment protocols and cloud-based software.
The company recently completed a pilot study of its system in 20 adult and pediatric patients with drug-resistant epilepsy in which the patients experienced a 44 percent reduction in seizure frequency in the eight weeks post-treatment.
Upcoming Events
-
11Jul
-
18Jul
-
21Oct